在中国,灭活SARS-CoV-2疫苗(国药BBIBP-CorV)与四价裂解病毒体灭活流感疫苗及23价肺炎球菌多糖疫苗联合接种的免疫原性和安全性:一项多中心、非劣效、开放标签、随机对照4期试验
该4期随机对照试验在中国社区招募≥18岁参与者,按1:1:1随机分为三组:SARS-CoV-2疫苗+IIV4/PPV23组、仅SARS-CoV-2疫苗组、仅IIV4/PPV23组,疫苗间隔28天接种。结果显示联合接种组SARS-CoV-2中和抗体血清转换率(100% vs 100%)和GMT(159.13 vs 173.20;GMT比值0.92[95%CI 0.83-1.02])非劣效于单独接种组;除B/Yamagata株血清转换率外,流感抗体非劣效;肺炎球菌IgG抗体非劣效。所有疫苗耐受性良好。
要点
- 联合接种组SARS-CoV-2中和抗体血清转换率100% vs 100%,GMT 159.13 vs 173.20,GMT比值0.92(95%CI 0.83-1.02),非劣效于单独接种组。
- 除B/Yamagata株血清转换率外,联合接种组流感病毒抗体非劣效于IIV4/PPV23组。
- 联合接种组肺炎球菌IgG抗体非劣效于IIV4/PPV23组,所有疫苗耐受性良好。
核心结论
- 灭活SARS-CoV-2疫苗与IIV4/PPV23联合接种安全且免疫原性令人满意。
研究设计与样本
- 多中心、非劣效、开放标签、随机对照4期试验;2021年3月10日至15日招募1152名≥18岁社区参与者,按1:1:1随机分组(每组384人),1132人纳入符合方案集(联合接种组375人、SARS-CoV-2疫苗组380人、IIV4/PPV23组377人);疫苗间隔28天接种,第0、28、56天采血。
主要发现
- 联合接种组SARS-CoV-2中和抗体血清转换率100% vs 100%,GMT 159.13 vs 173.20,GMT比值0.92(95%CI 0.83-1.02),非劣效于SARS-CoV-2疫苗组;除B/Yamagata株血清转换率外,联合接种组流感病毒抗体血清转换率和GMT非劣效于IIV4/PPV23组;联合接种组肺炎球菌IgG抗体血清转换率和GMC非劣效于IIV4/PPV23组;所有疫苗耐受性良好。
关键数值与推荐
- SARS-CoV-2中和抗体:联合接种组血清转换率100% vs SARS-CoV-2疫苗组100%,GMT 159.13 vs 173.20,GMT比值0.92(95%CI 0.83-1.02),非劣效。
- 流感病毒抗体:除B/Yamagata株血清转换率外,联合接种组血清转换率和GMT非劣效于IIV4/PPV23组。
- 肺炎球菌IgG抗体:联合接种组血清转换率和GMC非劣效于IIV4/PPV23组。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The safety and immunogenicity of the coadministration of an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV), quadrivalent split-virion inactivated influenza vaccine (IIV4), and 23-valent pneumococcal polysaccharide vaccine (PPV23) in adults in China is unknown. METHODS: In this open-label, non-inferiority, randomised controlled trial, participants aged ≥ 18 years were recruited from the community. Individuals were eligible if they had no history of SARS-CoV-2 vaccine or any pneumonia vaccine and had not received an influenza vaccine during the 2020-21 influenza season. Eligible participants were randomly assigned (1:1:1), using block randomization stratified, to either: SARS-CoV-2 vaccine and IIV4 followed by SARS-CoV-2 vaccine and PPV23 (SARS-CoV-2 + IIV4/PPV23 group); two doses of SARS-CoV-2 vaccine (SARS-CoV-2 vaccine group); or IIV4 followed by PPV23 (IIV4/PPV23 group). Vaccines were administered 28 days apart, with blood samples taken on day 0 and day 28 before vaccination, and on day 56. RESULTS: Between March 10 and March 15, 2021, 1152 participants were recruited and randomly assigned to three groups (384 per group). 1132 participants were included in the per-protocol population (375 in the SARS-CoV-2 + IIV4/PPV23 group, 380 in the SARS-CoV-2 vaccine group, and 377 in the IIV4/PPV23 group). The seroconversion rate (100 % vs 100 %) and GMT (159.13 vs 173.20; GMT ratio of 0.92 [95 % CI 0.83 to 1.02]) of SARS-CoV-2 neutralising antibodies in the SARS-CoV-2 + IIV4/PPV23 group was not inferior to those in the SARS-CoV-2 vaccine group. The SARS-CoV-2 + IIV4/PPV23 group was not inferior to the IIV4/PPV23 group in terms of seroconversion rates and GMT of influenza virus antibodies for all strains except for the seroconversion rate for the B/Yamagata strain. The SARS-CoV-2 + IIV4/PPV23 group was not inferior to the IIV4/PPV23 group regarding seroconversion rates and GMC of Streptococcus pneumoniae IgG antibodies specific to all serotypes. All vaccines were well tolerated. CONCLUSIONS: The coadministration of the inactivated SARS-CoV-2 vaccine and IIV4/PPV23 is safe with satisfactory immunogenicity. This study is registered with ClinicalTrials.gov, NCT04790851.
引用
- Chen H, Huang Z, Chang S, et al. Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV) coadministered with quadrivalent split-virion inactivated influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in China: A multicentre, non-inferiority, open-label, randomised, controlled, phase 4 trial. Vaccine. 2022. PMID: 35931636. doi:10.1016/j.vaccine.2022.07.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。